CHRISTOPHER J. COUGHLIN - Corporate Board Profile

CENTENE CORP

Filing Date	Source Excerpt
2022-03-11	Christopher J. Coughlin Principal Occupation: Retired Executive Vice President and Chief Financial Officer, Tyco International Ltd. First Became Director: January 2022 Age: 69 Mr. Coughlin was Senior Advisor to the CEO and Board of Directors of Tyco International from 2010 to his retirement in 2012. He served as Executive Vice President and CFO of Tyco from 2005 to 2010, during which he was instrumental in turning the company around after a management and financial scandal and ultimately separated it into six separate public companies. Prior to joining Tyco, he worked as the Chief Operating Officer of the Interpublic Group of Companies from June 2003 to December 2004 and as Chief Financial Officer from August 2003 to June 2004. Previously, Mr. Coughlin was Executive Vice President and Chief Financial Officer of Pharmacia Corporation from 1998 until its acquisition by Pfizer in 2003. He currently serves as a director of Karuna Therapeutics, Inc. and Prestige Consumer Healthcare, Inc. He previously served as a director of large and complex healthcare companies including Allergan plc, Alexion Pharmaceuticals, Inc., Covidien plc, as well as Hologic Inc., Dun & Bradstreet Corp and Forest Laboratories, LLC. Mr. Coughlin was recently named a 2022 Director of the Year by the New Jersey Chapter of the National Association of Corporate Directors (NACD) for his leadership in public corporate governance. In 2015, Mr. Coughlin was also named the NACD Corporate Director of the Year. Qualifications: Mr. Coughlin's range of experience includes, in particular, public company governance, healthcare, and chief financial officer roles. Board Member Audit Committee Compensation Committee Nominating and Governance Committee (Chairman) Environmental and Social Responsibility Committee Director Compensation The following table summarizes the compensation of our non-employee directors for the fiscal year ended December 31, 2021: Name Fees Earned or Paid in Cash ($) Stock Awards ($)1 Option Awards ($)1 All Other Compensation ($)2 Total ($) John R. Roberts 50,000 342,800 — 27,257 420,057
2023-03-24	AGE: 70 DIRECTOR SINCE: January 2022 RACE/ETHNICITY AND GENDER: White Male COMMITTEES: Audit and Compliance, Compensation and Talent (Chair) Christopher J. Coughlin Retired Executive Vice President and Chief Financial Officer, Tyco International Ltd.
2024-03-28	Christopher J. Coughlin \| 71 Retired Executive Vice President and Chief Financial Officer, Tyco International Ltd. Board Committees Audit and Compliance;Compensation and Talent (Chair) Race/Ethnicity and Gender: White Male Director Compensation Table Christopher J. Coughlin Fees Earned or Paid in Cash: 120,000 Stock Awards: 224,983 All Other Compensation: 25,000 Total: 369,983
2025-03-27	Christopher J. Coughlin \| 72 Retired Executive Vice President and Chief Financial Officer, Tyco International Ltd. Director Since: January 2022 Independent Yes Board Committees Audit and Compliance; Compensation and Talent (Chair) ... For 2024, non-employee directors received an annual cash retainer of $100,000 ... Christopher J. Coughlin Fees Earned or Paid in Cash $120,000 Stock Awards $224,969 All Other Compensation $25,000 Total $369,969

HOLOGIC INC

Filing Date	Source Excerpt
2016-01-20	Christopher J. Coughlin Age: 63 Director Nominee No committees listed No compensation listed
2017-01-20	Christopher J. Coughlin Former Executive Vice President and CFO Tyco International Age: 64 Director Since: 2016 Current Committee Membership: Audit and Finance (chair) 2016 Director Compensation Table: Fees Earned or Paid in Cash: $35,000, Stock Awards: $87,469, Option Awards: $87,492, Total: $209,961

Filing Date

Source Excerpt

2016-01-20

Christopher J. Coughlin Age: 63 Director Nominee No committees listed No compensation listed

2017-01-20

Christopher J. Coughlin Former Executive Vice President and CFO Tyco International Age: 64 Director Since: 2016 Current Committee Membership: Audit and Finance (chair) 2016 Director Compensation Table: Fees Earned or Paid in Cash: $35,000, Stock Awards: $87,469, Option Awards: $87,492, Total: $209,961

Prestige Consumer Healthcare Inc.

Filing Date	Source Excerpt
2019-06-28	Mr. Coughlin earned a bachelor’s degree in Accounting from Boston College.
2020-06-29	Mr. Coughlin earned a Bachelor’s degree in Accounting from Boston College.
2021-06-29	Christopher J. Coughlin has served as a director since August 2019. Mr. Coughlin served as Senior Advisor to the CEO and Board of Directors of Tyco International, Ltd., a diversified holding company, from 2010 until he retired in September 2012. Prior to that, he was Executive Vice President and Chief Financial Officer of Tyco International from 2005 to 2010. During his tenure, he played a central role in the separation of Tyco into five independent, public companies. Prior to joining Tyco, he worked as the Chief Operating Officer of the Interpublic Group of Companies from June 2003 to December 2004 and as Chief Financial Officer from August 2003 to June 2004. Previously, Mr. Coughlin was Executive Vice President and Chief Financial Officer of Pharmacia Corporation from 1998 until its acquisition by Pfizer in 2003. Prior to that, he was Executive Vice President of Nabisco Holdings and President of Nabisco International. From 1981 to 1996, he held various positions, including Chief Financial Officer, at Sterling Winthrop. Mr. Coughlin earned a Bachelor’s degree in Accounting from Boston College.
2022-06-28	Christopher J. Coughlin has served as a director since August 2019. Mr. Coughlin served as Senior Advisor to the CEO and Board of Directors of Tyco International, Ltd., a diversified holding company, from 2010 until he retired in September 2012. Prior to that, he was Executive Vice President and Chief Financial Officer of Tyco International from 2005 to 2010. During his tenure, he played a central role in the separation of Tyco into five independent, public companies. Prior to joining Tyco, he worked as the Chief Operating Officer of the Interpublic Group of Companies from June 2003 to December 2004 and as Chief Financial Officer from August 2003 to June 2004. Previously, Mr. Coughlin was Executive Vice President and Chief Financial Officer of Pharmacia Corporation from 1998 until its acquisition by Pfizer in 2003. Prior to that, he was Executive Vice President of Nabisco Holdings and President of Nabisco International. From 1981 to 1996, he held various positions, including Chief Financial Officer, at Sterling Winthrop. Mr. Coughlin serves on the boards of Karuna Therapeutics, Inc. (clinical-stage biopharmaceutical), as Lead Independent Director and Centene Corporation (healthcare enterprise). Mr. Coughlin previously served on the boards of Allergan plc, as Lead Independent Director, the Dun & Bradstreet Corp, as non-executive chairman, Hologic, Inc., Covidien Ltd, Dipexium Pharmaceuticals, Inc., Forest Laboratories, Inc., Interpublic Group of Companies, Monsanto Company, Perrigo Company and Alexion Pharmaceuticals, Inc. Mr. Coughlin earned a bachelor’s degree in Accounting from Boston College.

Filing Date

Source Excerpt

2019-06-28

Mr. Coughlin earned a bachelor’s degree in Accounting from Boston College.

2020-06-29

Mr. Coughlin earned a Bachelor’s degree in Accounting from Boston College.

2021-06-29

2022-06-28

Christopher J. Coughlin has served as a director since August 2019. Mr. Coughlin served as Senior Advisor to the CEO and Board of Directors of Tyco International, Ltd., a diversified holding company, from 2010 until he retired in September 2012. Prior to that, he was Executive Vice President and Chief Financial Officer of Tyco International from 2005 to 2010. During his tenure, he played a central role in the separation of Tyco into five independent, public companies. Prior to joining Tyco, he worked as the Chief Operating Officer of the Interpublic Group of Companies from June 2003 to December 2004 and as Chief Financial Officer from August 2003 to June 2004. Previously, Mr. Coughlin was Executive Vice President and Chief Financial Officer of Pharmacia Corporation from 1998 until its acquisition by Pfizer in 2003. Prior to that, he was Executive Vice President of Nabisco Holdings and President of Nabisco International. From 1981 to 1996, he held various positions, including Chief Financial Officer, at Sterling Winthrop. Mr. Coughlin serves on the boards of Karuna Therapeutics, Inc. (clinical-stage biopharmaceutical), as Lead Independent Director and Centene Corporation (healthcare enterprise). Mr. Coughlin previously served on the boards of Allergan plc, as Lead Independent Director, the Dun & Bradstreet Corp, as non-executive chairman, Hologic, Inc., Covidien Ltd, Dipexium Pharmaceuticals, Inc., Forest Laboratories, Inc., Interpublic Group of Companies, Monsanto Company, Perrigo Company and Alexion Pharmaceuticals, Inc. Mr. Coughlin earned a bachelor’s degree in Accounting from Boston College.

Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22